Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Fennec Pharmaceuticals Inc PO BOX 13628 68 TW ALEXANDER DRIVE DURHAM NC 27709 USA

www.fennecpharma.com P: 919-636-4530

Description:

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 248,236
Enterprise Value, $K 264,676
Shares Outstanding, K 27,100
Annual Sales, $ 21,250 K
Annual Net Income, $ -16,050 K
Last Quarter Sales, $ 9,740 K
Last Quarter Net Income, $ -2,690 K
EBIT, $ -12,780 K
EBITDA, $ -12,490 K
60-Month Beta 0.38
% of Insider Shareholders 11.25%
% of Institutional Shareholders 55.51%
Float, K 24,051
% Float 88.75%
Short Volume Ratio 0.39

Growth:

1-Year Return 12.87%
3-Year Return 193.12%
5-Year Return 318.26%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -20.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.10 on 03/21/24
Latest Earnings Date 05/09/24
Earnings Per Share ttm -0.61
EPS Growth vs. Prev Qtr -42.86%
EPS Growth vs. Prev Year 61.54%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 11/29/21

FENC Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 84.00
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -73.64%
Profit Margin % -75.53%
Debt/Equity -2.56
Price/Sales 11.57
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.43
Interest Coverage -3.73
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar